Background. Lumbar spinal stenosis is a common condition that causes axial low back pain, radicular pain, and neurogenic claudication. Epidural steroid injections are commonly used for the treatment of radicular symptoms and neurogenic claudication associated with symptomatic lumbar spinal stenosis. No prior study has evaluated whether transforaminal or interlaminar epidural steroid injections produce better clinical outcomes.
Methods. For each technique, 19 patients were retrospectively identified who received their first fluoroscopically guided epidural steroid injection for radicular and neurogenic claudication symptoms caused by lumbar spinal stenosis over a 12-month interval. All patients had corresponding MRI findings and had failed previous non-invasive therapies. Outcomes included the visual analog scale (VAS, 0-10 scale) immediately before the injection, immediately after the injection, and upon follow up at 4-6 weeks. Surgery rates and number of repeat injections over a 3 year period were also analyzed. The patient groups were matched for age and level of stenosis on MRI.
Results. There was no statistically significant difference between the two groups in pre injection to follow up VAS scores (P = 0.919). The difference between number of repeat injections between the interlaminar and transforaminal groups was not statistically significant (0.91-mean 2.47 and 2.58, respectively). Both the interlaminar and transforaminal groups experienced statistically significant improvement in VAS scores from before the injection to after the injection, and on follow up. Low numbers underwent surgery (11% in the interlaminar group vs 15% in the transforaminal group, not significant, P = 0.63).
Conclusions. In the current study, neither transforaminal nor interlaminar steroid injections resulted in superior short term pain improvement or fewer long term surgical interventions or repeat injections when compared with each other. Key Words. Epidural Injections; Radiculopathy; Spinal Stenosis; Rehabilitation; Pain; Spine; Injections
Background
Lumbar spinal stenosis (LSS) describes an anatomic state of narrowing of the intraspinal canal, narrowing of the lateral recess or narrowing of the neural foramen. LSS can be congenital or acquired [1] . Acquired LSS is usually from degenerative conditions but may due to space-occupying lesions or fibrosis. For the purposes of describing the prevalence of LSS, relative LSS has been defined as a spinal canal with an anterior-posterior diameter of less than 12 mm, while absolute LSS has been defined as having an anterior-posterior diameter of 10 mm or less [2] . In the general population, the overall prevalence of relative and absolute congenital LSS has been estimated at 4.7 and 2.6%, respectively [2] . The overall prevalence of relative and absolute acquired LSS has been estimated at 47.2% and 19.4%, respectively, [2] . Symptoms include low back pain, neurogenic claudication, and radicular pain [3] .
Epidural steroid injections (ESI) are used in the treatment of spinal pain and radicular pain [4] [5] [6] [7] . In the lumbar spine, specific diagnoses treated by ESI include symptomatic herniated nucleus pulposus, failed back surgery syndrome and symptomatic lumbar spinal stenosis [8, 9] . There is strong evidence showing ESI offer short-term relief of radicular pain [10] . Several studies have demonstrated that ESI may have a beneficial effect in relieving radicular pain symptoms secondary to LSS [5, 7, [11] [12] [13] [14] .
Both the interlaminar epidural approach [11] and transforaminal approach [13] have been shown to be effective treatments for short term relief of LSS related pain. To our knowledge, there is no prior study that compares different ESI techniques. A previous studied demonstrated that for symptomatic intervetebral disc herniations, transforaminal ESI were superior to interlaminar ESI [15] . Neither method was shown to be superior for achieving pain reduction in patients with axial back pain resulting from herniated intervertebral discs and spinal stenosis [16] .
The goal of this study was to compare short-tem improvement in pain and long-term surgical rates and the need for repeat injections between interlaminar ESI and transforaminal ESI for symptomatic lumbar spinal stenosis. Our hypothesis was that transforaminal ESI would provide better clinical outcomes than interlaminar ESI, based on previous data for intervertebral disc herniations.
Methods
This study was conducted at a large academic spine center and was approved by the University's Institutional Review Board. The study did not receive any external funding.
This study was a retrospective case control study of patients who had underwent either transforaminal or interlaminar ESIs for symptomatic lumbar spinal stenosis. Patients were identified who received an ESI for symptomatic LSS in a given 12-month interval during 2007. All injections were performed in an ambulatory surgery center connected with the spine center by the same physician experienced in performing the procedures (M.K.S.). There were no specific clinical or anatomic considerations to determine whether a transforaminal or interlaminar approach was used in any given patient.
All injections were performed at or at the level below the most severe level of spinal stenosis on imaging studies. A GE 9800 C-arm with DSA capability was used for the procedures and anterior-posterior (AP), oblique and lateral films were obtained on all procedures for documentation purposes. Within 1 hour before the procedure, the patients were asked to rate their average combined back and leg pain during activity on the visual analog scale (VAS, 0-10 scale) by a nurse not involved in the performance of the procedure. The patients were not asked to differentiate between pain with walking, standing, or other activities.
For the transforaminal approach, a 25-or 22-gauge, 3 1 /2-or 5-inch spinal needle was used. The needle was placed in the superior and anterior aspect of the corresponding intervertebral foramen under frequent fluoroscopic guidance, using the standard technique. The needle was placed on the patient's symptomatic side. Needles were placed bilaterally in patients with bilateral symptoms. After the needle was determined radiographically to be in the appropriate position, 0.5-1 mL of non-ionic contrast material (Omnipaque 300) was injected to document appropriate contrast spread along the spinal nerve into the epidural space without intravascular uptake. Next, a combination of 80 mg of methylprednisolone acetate with 1-2 mL of lidocaine 2% was injected.
For the interlaminar epidural steroid injections, we used a modified the traditional paramedian approach: An 18-gauge, 3 1 /2-or 5-inch Tuohy needle was advanced into the posterior-lateral epidural space toward the symptomatic side, using the loss-of-resistance technique. This "directed lateral interlaminar approach" was performed in order to improve the delivery of the injectate to the site of pathology without increasing the technical difficulty or side effects of the procedure. For patients with bilateral symptoms, the needle was placed in the midline. After negative aspiration for cerebrospinal fluid and blood, 0.5-1 mL of nonioninc contrast material (Omnipaque 300) was injected to document appropriate contrast spread into the epidural space on the patient's symptomatic side (or in the midline for bilateral symptoms). Next, a combination of 80 mg of methylprednisolone acete with 2-3 mL of lidocaine 1% was injected. The patients were then brought to the recovery area. They were asked to rate their pain on the VAS scale within 1 hour of the injection, prior to departure from the injection suite. They were asked to sit, stand, and walk before rating their combined back and leg pain. The patients were then seen in follow up typically 4-6 weeks after injection. They were again asked to rate their current, activity dependent combined back and leg pain on the same 0-10 point VAS that was used when the procedure was performed.
All subjects were retrospectively identified through a list of all patients who underwent ESI at an academic spine center during a 12-month period. Inclusion criteria included low back pain with unilateral or bilateral leg pain of radicular nature and neuroclaudication symptoms caused by spinal stenosis, single or multi level spinal stenosis on recent MRI within 12 months of the first procedure as interpreted by a board-certified radiologist, failure to respond to noninvasive treatments, documented pre-injection VAS, post injection VAS and follow up VAS, and a documented minimum 3-year follow-up at the spine center. Exclusion criteria included known contraindications for epidural steroid injections as described elsewhere, previous lumbar epidural steroid injections within the preceding 12 months, previous lumbar spine surgery, unstable neurological deficits and cauda equina syndrome, patients with on-going workers compensation and personal injury claims. Pre VAS = initial, preinjection visual analog score (VAS); Post VAS = immediate post injection VAS; F/U VAS = 4-6 week follow up VAS; No. Repeat Inj = Number of repeat injections over 3-year period; Change (Pre VAS-F/U VAS) = Difference between initial VAS and 4-6 week follow up VAS; IL = interlaminar group; TF = Transforaminal Group; Std Dev = Standard Deviation; Minimum = minimum value; Maximum = maximum value; P-value = Pr > |t| using T-test analysis; Diff 1-2 = difference between IL and TF groups; Diff IL (pre -post) = difference between VAS scores in interlaminar group before injection and immediately following injection; Diff TF (pre -post) = difference between VAS scores in transforaminal group before injection and immediately following injection; Diff IL (pre -F/U) = difference between VAS scores in interlaminar group before injection and at follow up; Diff TF (pre -F/U) = difference between VAS scores in transforaminal group before injection and at follow up. Interlaminar group  17  2  11%  19  Transforaminal group  16  3  16%  19  Total  33  5  38 following 3-year period. The number of repeat ESI was also quantified.
Results
The mean age for the transforaminal group was 67.7 years; the mean age for the interlaminar group was 67.1 (Table 1) . Nine patients in each group demonstrated stenosis at he L5/S1 level; Seven patients in the transforaminal group and six patients in the interlaminar group showed stenosis at the L4/L5 level; one patient in each group had stenosis at the L2/L3 level; one patient in the transforaminal group and two patients in the interlaminar group were stenotic at both the L3/L4 and L4/L5 levels; one patient in each group demonstrated stenosis at the L3/4, L4/5, and L5/1 levels ( Table 2 ). There was also no difference in the baseline, pre-injection VAS scores. Baseline VAS scores were 7.58 for the interlaminar group vs 6.74 for the transforaminal group (P = 0.194).
Within each group, there was a decrease in VAS scores from pre-injection to post-injection. In the interlaminar group pain scores were reduced from a mean of 7.58 to a mean of 2.05 (P < 0.0001); in the transforaminal group pain scores were reduced from a mean of 6.74 to a mean of 1.95 (P < 0.0001) ( Table 3) . Independent sample t-test analysis was performed. There was no statistically significant difference in pain reduction between the two groups (P = 0.893) ( Table 3) . Within each group, a decrease in VAS scores from pre-injection pain scores to 4-6-week follow up was also noted. The number of patients that achieved equal to or greater than 50% reduction in pain from pre injection VAS to follow up was 7 of 19 patients in the interlaminar group and 6 of 19 patients in the transforaminal group. The number of patients that achieved complete relief of pain from pre-injection to follow up was 3 of 19 patients in both groups. In the interlaminar group, pain scores were reduced from a mean of 7.58 to a mean of 4.58 at follow-up (P = 0.0031); in the transforaminal group, pain scores were reduced from a mean of 6.74 to a mean of 4.68 at follow up (P = 0.0066- Table 3 ). There was no statistically significant difference between the two groups (P = 0.919).
The mean number of repeat injections over a 3-year follow-up period was 2.47 for the interlaminar group, and 2.58 for the transforaminal group. The difference between groups was not statistically significant (P = 0.91). In the interlaminar group, 5 of 19 patients received no repeat injections. In the transforaminal group 3 of 19 patients received no repeat injections. The number of patients in each group who underwent surgery in the 3-year follow up period was low. In the interlaminar group, 2 of 19 (11%) of subjects underwent surgery. In the transforaminal group, 3 of 19 (16%) underwent surgery (Table 4) . Chi-square analysis was used. The difference was not significant (P = 0.63- Table 5 ).
Discussion
To our knowledge, this is the first study that compared interlaminar epidural steroid injections (ESI) to transforaminal ESI for the treatment of lumbar spinal stenosis (LSS). This study is novel in that it matched patients by both age and anatomical level of stenosis. Our data demonstrate that within each group, pain scores decreased significantly from pre-procedure to immediate post-procedure and 4-6-week follow-up. In addition, the interlaminar and transforaminal groups had relatively low surgery rates (11% and 16%, respectively) and low repeat numbers of injections over a 3-year period ( Table 4 ).
The study also demonstrates that in treating of symptomatic lumbar spinal stenosis with ESI, neither the interlaminar or transforaminal approach was superior. Although patients were matched by age and anatomical level of stenosis, they were not matched based on whether the stenosis was mainly in the lateral recess, central canal or intervertebral foramen. Subjects were also not matched based on etiology of stenosis, although all patients in the study had spinal stenosis caused by degenerative conditions.
There are several ways in which this study could be improved. First, this study had a relatively small sample size and represents the experience of one institution alone. Next, there are limitations of a retrospective series. These limitations include selection bias, recall bias, suboptimal control of external variables, and incomplete data sets. Assessing global and back specific function in addition to VAS scores would be a method to better qualify any difference in clinical outcomes between interlaminar and transforaminal ESI.
In the current study neither method resulted in superior short-term pain improvement, fewer long term surgical interventions or repeat injections. Further studies should determine if transforaminal injections result in better outcomes for certain forms of spinal stenosis. At least theoretically, one would expect that transforaminal injections are better for cases of foraminal stenosis compared to central stenosis. This study was not designed to answer this question, but should be investigated in the future. 
